Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
NEW YORK, Oct. 31, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Xerox Corporation (NYSE:XRX) securities between April 23, 2012 and October 23, 2015.
Click here to learn about the case: http://www.wongesq.com/pslra/xerox-corporation. There is no cost or obligation to you.
According to the complaint, during the Class Period the Company violated securities laws by failing to disclose that: (a) the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; and (b) the Company would be unable to deliver Health Enterprise implementations at sustainable profits.
On October 26, 2015, Xerox released third quarter 2015 financial results that missed analysts’ estimates due in part to a $385 million pre-tax charge and lost revenues relating to assets and unrecoverable costs associated with its Health Enterprise implementation projects and the termination of Health Enterprise’s California and Montana projects. Following this news, shares of Xerox fell from a class period high of $13.57 per share on December 5, 2014, to a close of $9.01 per share on October 27, 2015.
If you suffered a loss in Xerox you have until December 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/xerox-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
